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Agouti Expression in Human Adipose Tissue
Functional Consequences and Increased Expression in
Type 2 Diabetes
Steven R. Smith,1 Barbara Gawronska-Kozak,1 Lenka Janderová,1 Taylor Nguyen,1 Angela Murrell,1
Jacqueline M. Stephens,2 and Randall L. Mynatt1

It is well recognized that the agouti/melanocortin system is an important regulator of body weight homeostasis. Given that agouti is expressed in human adipose
tissue and that the ectopic expression of agouti in
adipose tissue results in moderately obese mice, the
link between agouti expression in human adipose tissue
and obesity/type 2 diabetes was investigated. Although
there was no apparent relationship between agouti
mRNA levels and BMI, agouti mRNA levels were significantly elevated in subjects with type 2 diabetes. The
regulation of agouti in cultured human adipocytes revealed that insulin did not regulate agouti mRNA,
whereas dexamethasone treatment potently increased
the levels of agouti mRNA. Experiments with cultured
human preadipocytes and with cells obtained from
transgenic mice that overexpress agouti demonstrated
that melanocortin receptor (MCR) signaling in adipose
tissue can regulate both preadipocyte proliferation and
differentiation. Taken together, these results reveal
that agouti can regulate adipogenesis at several levels
and suggest that there are functional consequences of
elevated agouti levels in human adipose tissue. The
influence of MCR signaling on adipogenesis combined
with the well-established role of MCR signaling in the
hypothalamus suggest that adipogenesis is coordinately
regulated with food intake and energy expenditure.
Diabetes 52:2914 –2922, 2003

O

ver the past decade, it has become apparent
that the agouti/melanocortin system is a critical
component of several biological pathways, including body weight homeostasis. Many genetic and pharmacological studies have shown that agouti
and agouti-related protein (AGRP) compete with proopiomelanocortin (POMC)-derived peptides for binding
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sites on melanocortin receptors (MCRs) to regulate food
intake and energy expenditure. Altered expression levels
of agouti (1,2), AGRP (3,4), MC3-R (5) and MC4-R (6), and
POMC (7) have been shown to disrupt the control of body
weight in mice. However, to date, there have been no
published observations implicating agouti, per se, in human obesity or type 2 diabetes.
The mouse and human agouti proteins are structurally
similar, but the expression pattern of the mouse and
human agouti genes is very different. The transcription of
the wild-type mouse agouti is temporally regulated, being
expressed solely in the skin during part of the hair growth
cycle (1). Human agouti is expressed in diverse tissues:
adipose tissue, testis, heart, liver, kidney, ovary, and skin
(8,9). The divergence in expression patterns between mice
and humans strongly suggests that agouti may have functions other than pigmentation in humans. The presence of
agouti, and MCRs, in human adipose tissue raises questions as to their normal function in adipose tissue and
whether dysregulation of agouti in adipose tissue might be
associated with an obese, insulin-resistant, or diabetic
phenotype.
In the original human agouti cloning study by Kwon et
al. (8), an RT-PCR analysis of RNA obtained from subcutaneous fat from three normal females revealed agouti
expression in two of the three fat samples and suggested
that agouti might be differentially regulated in humans.
More recently, agouti mRNA was found to be negatively
correlated with BMI in men but not in women (10). In our
recent studies, we engineered transgenic mice to overexpress agouti in adipose tissue in order to study the
potential biological role of agouti/melanocortin signaling
in human adipose tissue (11). The aP2-agouti transgenic
mice become significantly heavier than nontransgenic
littermates by 8 –10 weeks of age and have almost a
twofold increase in fat mass compared with nontransgenic
mice (12). Moreover, there were no detectable changes in
food intake in the aP2-agouti mice, suggesting changes in
energy utilization and/or nutrient partitioning (13).
In the present study, expression levels of human agouti
and MCRs were studied in human mesenchymal stem cells
as they were differentiated into lipid-storing adipocytes.
Having established the presence of both agouti and MCRs
in human adipose tissue, agouti expression levels were
measured in patients with a wide range in BMI and in
patients with type 2 diabetes. Additionally, experiments
with transgenic mice that express agouti in adipose tissue
DIABETES, VOL. 52, DECEMBER 2003
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and isolated preadipocytes were used to determine
whether there was a possible functional role of the agouti/
melanocortin system in adipose tissue. Several interesting
findings have emerged from these experiments. The data
demonstrate that human agouti expression is upregulated
by glucocorticoids and that agouti and the cortisol-producing enzyme 11␤ hydroxysteroid dehydrogenase type 1
(11␤-HSD-1) are upregulated in patients with type 2 diabetes. Third, we find that the agouti/melanocortin system
is a potent and direct regulator of adipogenesis.
RESEARCH DESIGN AND METHODS
Human mesenchymal cell differentiation. Cells (BioWhittaker) were
plated at a density of 2–5 ⫻ 103/cm2 and grown at 37°C in an atmosphere of
95% air and 5% CO2 as previously described (14). Cells were grown to 100%
confluence in the growth medium supplemented with 5% fetal bovine serum
(FBS). Five-day postconfluent cells were incubated in adipogenesis induction
medium (AIM-M199; 1 mmol/l dexamethasone, 0.2 mmol/l indomethacin, 170
nmol/l insulin, 0.5 mmol/l isobutyl-methylxanthine [IBMX], 10% FBS, 0.05
units/ml penicillin, and 0.05 g/ml streptomycin) for 3 days. Next, the cells
were incubated for 1 day in adipogenesis maintenance medium (AMM-M199;
170 nmol/l insulin, 10% FBS, 0.05 units/ml penicillin, and 0.05 g/ml streptomycin) and then switched to AIM for 3 days. After a third exposure to AIM,
cells were maintained in AMM for up to 21 days after the initiation of
differentiation.
Isolation and differentiation of mouse preadipocytes. Epididymal and
inguinal fat pads, collected from 19- to 21-day-old FVB, ␤-actin promoteragouti (BAP-agouti), and aP2-agouti mice, were minced and digested with
collagenase class I (2 mg/ml; Worthington Biochemical) in a shaking bath for
1 h at 37°C. Dissociated cells were filtered through a 100 mol/l cell strainer
(Becton Dickinson Labware) and separated by centrifugation at 360g for 5
min. Pelleted preadipocyte cells were resuspended for 1 min. in erythrocyte
lysis buffer (Sigma) to remove erythrocyte contamination and centrifuged at
360g for 5 min. Cells were plated in 35-mm Petri dishes (p ⫽ 0) in DMEM/F12
medium (Invitrogen Life Technologies) supplemented with 15% of FBS
(Invitrogen Life Technologies) or in complete medium. Subconfluent primary
cultures were trypsynized and replated (p ⫽ 1) at 2 ⫻ 104/cm2 in a 24-well
culture plate and kept in complete medium. At confluency, cells received
differentiation medium (DMEM/F12 with 5% FBS supplemented with 1.7
mol/l insulin, 1 mol/l dexamethasone, and 0.5 mmol/l IBMX for 5 days. In
the experiment in which RNA was collected from the adipocytes, the medium
was replaced with DMEM/F12 with 5% FBS for 2 additional days in the
presence of 2 mol/l rosiglitazone and 10 nmol/l insulin. To measure lipid
content in the adipocytes, cells were fixed in 10% solution of formaldehyde in
aqueous phosphate buffer for ⱖ1 h, washed with 60% isopropanol, and stained
with Oil Red-O solution (in 60% isopropanol) for 10 min. The cells were then
repeatedly washed with water, photographed, and destained in 100% isopropanol for 15 min. The optical density of the isopropanol solution was
measured at 500 nm.
Human biopsies. All human studies were performed after institutional
review board approval and written informed consent were obtained. After
local anesthesia, adipose tissue was collected by needle biopsy of the
superficial subcutaneous adipose tissue lateral to the umbilicus.
Mice. Transgenic mice were maintained on the FVB/N background at the
Pennington Biomedical Research Center as previously described (11). All
mice were fed a diet containing 11% fat by weight (Mouse Diet 5015; Purina
Mills). Food and water were provided ad libitum. All data are from mice that
are hemizygous for the transgene or their nontransgenic littermates.
RNA isolation and RT-PCR analysis. Total RNA was isolated by the Trizol
method (Life Technologies) and applied to Rneasy columns (Qiagen). The
concentration of RNA was determined using spectrophotometry, and the
quality was verified by visualizing on a gel. For nonquanitative RT-PCR, 1 g
total RNA was used for the cDNA synthesis and 1:40 of that reaction was used
as a PCR template.
The following primer sets were used. Human (forward, reverse primer):
agouti (TGTCTCTATTGTGGCGCTGAA, GGAAGAAGCGGCACTG); MC1-R
(GCAGCAGCTGGACAATGTCA, ATGAAGAGCGTGCTGAAGACG); MC2-R (A
TCACCTTCACGTCGCTGTT, CGTTATTCCCATGGATTCTA); MC3-R (CCAAA
AGAAGTATCTGGAG, AGTTCATGCCGTTGCAGCC); MC4-R (GCTACGAGCA
ACTTTTTCTC, GTACTGGAGAGCATAGAAG); MC5-R (ACCTGCACTCCCCC
ATGTAC, CAGGCACTGGACATGCTCAC); peroxisome proliferator–activated
receptor (PPAR)␥ (TGCCAAAAGCATTCCTGGTT, CGCTGTCATCTAATTCCA
GTGC); adipsin (CAGGGTCACCCAAGCAACA, CAGGGTCACCCAAGCAA
CA); cyclophilin (GGAGATGGCACAGGAGGAAA, CGTAGTGCTTCAGTTTGA
DIABETES, VOL. 52, DECEMBER 2003

AGTTCTCA). Mouse (forward, reverse primer): MC1-R (CACTCAGGAGCCC
CAGAAGA, CACCAGACTCACCAGCCCTAG); MC2-R (GCGCCGCACCATC
ATC, GGGAGCGGGCAAGTAAGAAC); MC3-R (CTCTGGGCATCGTCAGTC
TGA, GGATAAACTGGTCCTCCAAGGTC); MC4-R (GCGGGTCGGGATCA
TCA, GGTACCCTGGCGGATGGT); MC5-R (AGGTGTTCCTGACCCTGGGT,
CAGGCATTGGACATGCTCAC); PPAR␥ (AGAGTCTGCTGATCTGCGAGC, CG
GATCGAAACTGGCACC); aP2 (GTGATGCCTTTGTGGGAACC, CGCCCAGTT
TGAAGGAAATCT); cyclophilin (TCCATCGTGTCATCAAGGACTT, CTCATCT
GGGAAGCGCTCA).
The taqman probe primer system (Applied Biosystems) was used for quantitative RT-PCR. Primer/probe sets are as follows. Agouti: forward CAACTCC
T-CTGTGAACCTACTGGAT, probe 6-FAM-CCCTTCTGTCTCTATTGTGgcGCT
GAAC-BHQ (lower case letters denote intro/exon boundry), reverse TGCCG
ATCTGTTTGGATTTCT; 11␤-HSD-1: forward GGCTTATCATCTGGCGAAG
ATG, probe 6-FAM-GGATACCACCTTCTGTAGAGTTTCTTTT-BHQ, reverse
ACCTCGCTGTCACCACCACATGGG. RT-PCR was carried out in one tube
using the ABI PRISM 7700 SDS instrument (Applied Biosystems) using 50 ng
total RNA as the template. The master mix included 300 nmol/l primers, 100
nmol/l probe, reverse transcriptase MuLV, RNase inhibitor, and AmpliTaq
GOLD (Applied Biosystems). The Ct value for every sample was measured in
duplicate, and mRNA levels were normalized to cyclophilin mRNA levels
(forward GGAGATGGCACAGGAGGAAA, probe 6-FAM-CATCTACGGTGAGC
GCTTCCCCG-BHQ, reverse CGTAGTGCTTCAGTTTGAAGTTCTCA). The
agouti and MCR PCR products were cloned into a T/A cloning vector and
sequenced.
Cell proliferation assay. Human preadipocytes were purchased from Zen
Bio. The donors were five healthy women between 20 and 60 years of age. The
average BMI was 26.6 kg/m2, and none were morbidly obese. Preadipocytes
were isolated by centrifugal force after collagenase treatment. We received
undifferentiated preadipocytes at passage 2 and plated equal numbers of cells
in a 96-well plate. The cells were cultured in DMEM/F-10 (1:1 [vol/vol]) with
10% FBS until ⬃50% confluence. The human cells were then treated with the
various combinations of ␣ melanocyte-stimulating hormone (␣MSH) and
murine agouti (93aa-132aa; Phoenix Pharmaceuticals) overnight. The next
morning, fresh media containing BrdU was added. Three hours later, BrdU
uptake was measured by enzyme-linked immunosorbent assay (ELISA) (Amersham Pharmacia). For mouse preadipocyte proliferation assays, preadipocytes were isolated from 19- to 21-day-old mice by collagenase digestion and
centrifugation. The preadipocytes were grown to confluence, trypsinized, and
split equally into 96-well plates. The mouse cells were then treated with the
various combinations of ␣MSH and agouti overnight. The next morning, fresh
media containing BrdU was added. Three hours later, BrdU uptake was
measured by ELISA (Amersham Pharmacia).
Statistical analyses. Unpaired t tests were used to compare diabetic and
nondiabetic individuals (JMP version 4.0; SAS Institute, Cary, NC). Agouti and
11␤-HSD-1 mRNA expression were compared across sex and diabetes status
using a two-way ANOVA. Correlation between agouti and BMI was performed
using Pearson correlation. Statistical significance was set a priori at 0.05.

RESULTS

The MCR status in FVB/N mouse adipose tissue and each
of the cell lines used in these experiments were tested
because different mouse strains may express different
MCR, receptor status may be affected by culture conditions, and cell lines can change over time. To our knowledge, there is only one publication on the expression of
MCRs in human adipose tissue, and this study indicates
that all MCRs are expressed in human subcutaneous fat
(15). In the present study, RNA was isolated from human
mesenchymal stem cells and 3T3-L1 cells as they differentiated into adipocytes, as described in RESEARCH DESIGN AND
METHODS. RNA was also obtained from intact mouse inguinal and human subcutaneous fat and from mouse adipose
tissue after it was fractionated into stromal vascular and
adipocyte fractions. The presence of all known MCR was
then examined by RT-PCR. As shown in Fig. 1A, both
MC1-R and MC2-R were detected in the human mesenchymal stem cells before and after differentiation and in
human adipose tissue. MC1-R was found predominately in
the preadipocyte fraction and MC2-R predominately in the
adipocyte fraction. The other MCRs were not detected in
2915
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FIG. 1. RT-PCR analysis of MCRs in mouse and human adipose tissue and adipocytes. A: RNA was isolated from human mesenchymal stem cells
as they were differentiated into adipocytes, as described in RESEARCH DESIGN AND METHODS (lanes 2-5), from preadipocytes that were isolated from
human subcutaneous fat and grown to confluence (lane 6) and after they were differentiated into adipocytes (lane 7) and from whole human
subcutaneous fat (lane 8). B: RNA was isolated from 3T3-L1 mouse adipocytes as they were differentiated into adipocytes, from whole mouse fat
pads, and from mouse fat that had been separated into the stromal vascular and adipocyte fractions by collagenase digestion and centrifugation.
C: RNA was isolated from mouse preadipocytes isolated from combined white fat depots and grown to confluence. For all samples, first-strand
cDNA was synthesized from 2 g total RNA and 1/40th of the reaction was used as template for 35 cycles of PCR.

human cells or fat. A critical problem with RT-PCR detection of MCR mRNA is that the MCR genes are intronless.
Therefore only a small amount of genomic DNA contamination in the RNA preparation will give a false-positive. It
is unclear if the human RNA purchased for the previous
study (15) was DNAse treated for the RT-PCRs. Hence, it
is possible that the commercial RNA may have been
contaminated with genomic DNA.
RT-PCR analysis detected both MC2-R and MC5-R in
murine 3T3-L1 cells (Fig. 1B) as they differentiated into
adipocytes, an observation which is consistent with a
previous study on the MCR subtype expression in 3T3-L1
adipocytes (16). None of the other MCR subtypes were
detectable in 3T3-L1 cells. MC2-R and MC5-R were detectable in FVB/N mouse adipose tissue, and they were found
primarily in the adipocyte fraction. MC1-R, MC2-R, and
MC5-R were found in mouse preadipocyte culture (Fig.
1C).
To examine the agouti expression pattern during human
adipocyte differentiation, human mesenchymal stem cells
were cultured to 95% confluence and induced to differentiate as described in RESEARCH DESIGN AND METHODS. We
observed that the expression of agouti mRNA increased
through each cycle of exposure to the differentiation
media and declined when the cells were returned to basal
2916

media (Fig. 2A and B). The decline in agouti expression
that occurred when cells were returned to the basal media
suggested that individual components of the differentiation media were capable of regulating agouti expression.
We observed that the addition of dexamethasone to either
confluent mesenchymal stem cells or differentiated adipocytes increased agouti expression to the same level observed with the complete differentiation cocktail (Fig. 2C).
These in vitro results indicate that glucocorticoids upregulate agouti expression in human adipocytes.
Since transgenic mice that express agouti in adipose
tissue become obese (12), agouti mRNA was quantitated in
the subcutaneous fat from humans with a broad range of
BMIs. There was no correlation between agouti expression levels and BMI in either men or women (Fig. 3A).
However, agouti mRNA was significantly greater in
women than in men (Fig. 3B). Agouti mRNA was also
measured in individuals with type 2 diabetes with body fat
similar to moderately obese people (Table 1 and Fig. 3A).
There were significantly higher levels of agouti expression
in diabetic subjects than in nondiabetic individuals (Table
1 and Fig. 3B). The data in Fig. 3A demonstrate that type
2 diabetic subjects have higher agouti levels than nondiabetic subjects across a range of BMIs. Again there was a
DIABETES, VOL. 52, DECEMBER 2003
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FIG. 2. Quantitation of agouti mRNA in human fat and adipocytes. A: RT-PCR analysis of agouti during the differentiation of human mesenchymal
stem cells into adipocytes. PPAR␥ and adipsin were measured as markers of differentiation. B: Quanitative RT-PCR of agouti during human
mesenchymal stem cell differentiation into adipocytes. Gray blocks show the times when cells were fed with adipocyte differentiation media (FBS
ⴙ insulin ⴙ dexamethasone [Dex] ⴙ IBMX). At all other times, the cells were fed with FBS and insulin. C: Regulation of agouti by dexamethasone
and IBMX in differentiated human adipocytes. Indom, indomethacin.

sex effect, with diabetic women having the highest overall
agouti expression levels (Fig. 3B).
Cell culture experiments with either confluent preadipocytes or differentiated adipocytes demonstrated that
glucocorticoids potently increase agouti expression. While
elevated glucocorticoid levels may play a significant role in
the development of obesity and type 2 diabetes (17), there
are no definitive reports linking elevated circulating glucocorticoid levels to the obese/diabetic state. Additionally,
we found no relationship between cortisol secretion (as
measured by salivary cortisol) and agouti mRNA (data not
shown). However, the enzyme 11␤-HSD-1 can regulate
intracellular glucocorticoid concentrations by regenerating active glucocorticoid (cortisol in humans, corticosterone in mice) from inactive cortisone and 11dehydrocorticosterone. We observed that 11␤-HSD-1
mRNA levels were significantly higher in the same cohort
of diabetic subjects that had elevated agouti expression
levels (Fig. 3C), demonstrating another correlation between glucocorticoids and agouti.
Having observed the elevated agouti levels in diabetic
humans, transgenic mice and cell culture experiments
were used to determine whether there were functional
consequences of agouti expression in adipose tissue. Microarray data from 3-week-old aP2-agouti transgenic mice
suggested a relationship between agouti expression and
preadipocyte hyperplasia (data not shown). Therefore, we
measured the DNA content from the epididymal fat pads
of aP2-agouti transgenic mice to determine cell density.
DIABETES, VOL. 52, DECEMBER 2003

Both total DNA and DNA per milligram fat were significantly higher in the transgenic mice at 4 weeks of age,
indicating that more preadipocytes were present in the fat
pads of aP2-agouti mice (Fig. 4A). The increased amount
of DNA in the fat of aP2-agouti mice led us to examine the
effects of agouti and ␣MSH on preadipocyte proliferation
in vitro. We observed that ␣MSH inhibited proliferation in
both mouse and human preadipocytes (Fig. 4B and C). Our
data also indicate that agouti has a slight stimulatory effect
on proliferation, but it is clear that agouti blocked the
inhibitory effects of ␣MSH. Interestingly, AGRP was not
able to block the inhibitory effects of ␣MSH on proliferation (data not shown). Forskolin was also a potent inhibitor of proliferation, but agouti was not able to block the
inhibitory effects of forskolin (data not shown). These
data, taken together with the increased DNA content at 4
weeks of age in the aP2-agouti mice, suggest that ␣MSH
and agouti regulate adipocyte proliferation in a reciprocal
fashion.
Several studies have shown that PPAR␥ is an essential
transcription factor for differentiation and maturation of
adipocytes (18 –24). Additionally, ectopic expression of
PPAR␥ in nonprecursor fibroblast cells promotes lipid
accumulation and confers the characteristics of mature
adipocytes (25). Recent studies have also suggested that
the STAT (signal transducers and activators of transcription) family of transcription factors may also be important
in fat cells (26 –29). We have previously shown that both
agouti treatment of 3T3-L1 adipocytes and agouti expres2917
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TABLE 1
Variables of the study population
Variable
Sex (F/M)
Race (black/white)
BMI (kg/m2)
Body fat (%)
Waist (cm)
Insulin (U/ml)
Glucose (mg/dl)
Triglyceride
(mg/dl)
HbA1c (diabetic
subjects only)
Agouti/cyclophilin
mRNA
11␤-HSD-1/
cyclophilin
mRNA

Nondiabetic
control

Diabetic

P
value

8/17
7/17
29.12 ⫾ 4.40
30.10 ⫾ 8.70
94.96 ⫾ 12.30
11.70 ⫾ 7.12
95.40 ⫾ 10.40

7/12
5/14
32.55 ⫾ 5.23
32.76 ⫾ 8.99
108.05 ⫾ 12.26
17.14 ⫾ 9.42
182.32 ⫾ 48.55

NA
NA
0.01
NS
⬍0.001
0.01
⬍0.001

139.68 ⫾ 63.34

230.16 ⫾ 206.23

0.01

N/A

7.71 ⫾ 1.85

NA

1.56 ⫾ 1.42

3.44 ⫾ 1.90

⬍0.001

0.61 ⫾ 0.11

1.15 ⫾ 0.10

⬍0.001

Data are means ⫾ SD.

FIG. 3. Expression of agouti and 11␤-HSD-1 mRNA in human subcutaneous adipose tissue. Agouti and 11␤-HSD-1 mRNAs were measured as
described in RESEARCH DESIGN AND METHODS and normalized to cyclophilin
mRNA. A: There was no relationship between BMI and agouti mRNA,
but agouti (B) and 11␤-HSD-1 (C) mRNA are increased in diabetes.
T2DM, type 2 diabetes.

sion in mouse adipose tissue increases STAT1, STAT3, and
PPAR␥ protein levels (13). Since PPAR␥ is a key regulator
of adipocyte differentiation and agouti induces PPAR␥, we
initiated experiments to address the ability of agouti to
influence adipocyte differentiation. The levels of differentiation were measured by lipid accumulation in nontransgenic and BAP-agouti transgenic mice (30). Cells from the
2918

BAP-agouti mice were included in this study because the
B-actin promoter will drive agouti expression in the preadipocytes. However, preadipocytes isolated from the aP2agouti mice should not express agouti because the aP2
promoter is not active until late in adipocyte differentiation. Preadipocytes were isolated from 19- to 21-day-old
mice by collagenase digestion and centrifugation. The
preadipocytes were plated and grown to confluence and
induced to differentiate as described in RESEARCH DESIGN AND
METHODS. After 5 days of differentiation, the cells were
stained with Oil Red-O to measure lipid accumulation.
Only ⬃20% of the cells from wild-type mice had significant
lipid accumulation (Fig. 5A). However, both the addition
of 10 nmol/l COOH-terminal agouti peptide to wild-type
preadipocytes (Fig. 5B) and the ectopic expression of
agouti (Fig. 5C) caused a significant increase Oil Red-O
staining. After photography, the Oil Red-O was extracted
from the adipocytes and quantified (Fig. 5D), further
demonstrating that agouti increases adipocyte differentiation. In a separate set of experiments, RNA was extracted
from the confluent preadipocytes and daily after addition
of the differentiation cocktail. PPAR␥ mRNA is already at
high levels in the confluent preadipocytes isolated for the
BAP-agouti transgenic mice. Additionally, aP2 mRNA appears earlier, and the band is more intense in the preadipocytes isolated from the transgenic mice. The data
presented in Fig. 5 demonstrate that agouti treatment of
preadipocytes from nontransgenic mice increases adipogenesis in vitro and that endogenous expression of agouti
increases adipogenesis in vitro and in vivo.
DISCUSSION

The hypothalamic melanocortin system is an important
regulator of body weight and appetite. The aim of these
studies was to understand the role of the melanocortin
system in adipose tissue. These studies reveal for the first
time that expression of agouti mRNA is increased in
diabetes, but not obesity, and that glucocorticoids upregulate agouti mRNA in vitro. They also reveal that there is
increased expression of the cortisol-activating enzyme
11␤-HSD-1 in diabetes. We also provide compelling data
DIABETES, VOL. 52, DECEMBER 2003
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FIG. 4. Effects of agouti preadipocyte proliferation. A: As an estimate of cell density, DNA content was measured in aP2-agouti and nontransgenic
mice at 4, 6, 8, and 10 weeks of age (n ⴝ 5–7 mice per data point). Data are presented as mean ⴞ SE. B and C: Preadipocytes from mice and humans
were isolated by centrifugal force after collagenase treatment. They were grown to confluence, trypsinized, and split equally into 96-well plates.
The cells were then treated with the various combinations of ␣MSH and agouti overnight. The next morning, fresh media containing BrdU was
added. Three hours later, BrdU uptake was measured by ELISA. Data are means ⴞ SE from three separate experiments. *P < 0.05 vs. control
values.

on the functional consequences of local agouti production;
␣MSH inhibits proliferation of human and murine preadipocytes, and agouti blocks this effect. Furthermore, agouti
enhances differentiation of murine and human preadipocytes in vitro. Combined with previous data demonstrating
that agouti upregulates PPAR␥ protein levels, this suggests
that agouti is a paracrine factor in adipose tissue that can
regulate both proliferation and differentiation of preadipocytes.
In addition to the effects of agouti on adipogenesis,
there is considerable precedence for the regulation of
mature adipocyte metabolism by agouti and POMC-derived peptides. The mRNA levels for fatty acid synthase
and stearoyl-CoA desaturase, two key enzymes in de novo
fatty acid synthesis and desaturation, respectively, were
dramatically increased in obese (Avy) mice relative to lean
DIABETES, VOL. 52, DECEMBER 2003

(a/a) controls (31). Additionally, treatment of fully differentiated 3T3-L1 adipocytes with recombinant agouti protein increased fatty acid synthase and stearoyl-CoA
desaturase mRNA levels (31). A potential mechanism for
the increased fatty acid synthase and stearoyl-CoA desaturase levels is that they are transcriptional targets of
PPAR␥. In opposition to the adipogenic effects of agouti,
ACTH, ␣MSH, and ␤-LPH are potent lipolytic hormones,
but considerable interspecies variability exists in the lipolytic response of adipocytes to melanocortins (32). The
negative effects of melanocortins on adipogenesis (inhibition preadipocyte proliferation and increased lipolysis),
combined with the positive effects of agouti on adipogenesis (increased PPAR␥ and differentiation), strongly suggest a coordinate control of the adipogenesis.
Agouti appears to antagonize ␣MSH and ACTH stimula2919
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FIG. 5. Effects of agouti on adipocyte differentiation The preadipocytes from nontransgenic mice and BAP-agouti (BAP-a) transgenic were plated
and grown to confluence in DMEM/F12 with 15% FBS. At confluence, the cells were trypinized and split equally into 12-well plates After reaching
confluence the cells were induced to differentiate by changing the medium to DMEM containing 10% FBS, 0.5 mmol/l 3-isobutyl-1-methylxanthine,
1 mol/l dexamethasone, and 1.7 mol/l insulin. After 48 h, this medium was replaced with DMEM/F12 supplemented with 15% FBS, and cells were
maintained in this medium for 2 more days until fixed and stained with Oil Red-O. A: Adipocytes from nontransgenic mice. B: Adipocytes from
nontransgenic mice treated with 10 nmol/l agouti from the start of differentiation. C: Adipocytes from BAP-agouti mice. D: After photography the
Oil Red-O was extracted from the adipocytes with isopropanol and quantitated via spectrophotometry. Data are presented as means ⴞ SE and
are from two independent experiments with four wells per treatment. E: In a separate experiment RNA was isolated from preadipocytes at
confluency and after initiation of differentiation. RT-PCR was used to detect mRNA for PPAR␥ and aP2 as markers of differentiation. OD, optical
density.

tion of cAMP at all five of the MCRs (33,34). ␣MSH
stimulates cAMP levels at all the MCRs except MC2-R, and
ACTH stimulates cAMP levels at all the MCRs (33). Previous studies demonstrated that mouse adipocytes express
high-affinity binding sites for melanocortin peptides (35)
and that MC1-R, MC2-R, and MC5-R are expressed in
adipocytes and adipose tissue (16,36). In these studies,
high expression levels of MC1-R and low levels of MC2-R
were observed in the human preadipocytes (Fig. 1), and
based on the inactivity of ␣MSH at MC2-R, it is logical to
suggest that MC1-R is responsible for the antiproliferative
effects of ␣MSH in preadipocytes.
It should be noted that the inhibitory effects of ␣MSH
cellular proliferation are not restricted to preadipocytes.
One of the hallmark phenotypes of the yellow obese
syndrome is neoplasia and an increased incidence of
tumors (reviewed by Wolff et al. [37] and Yen et al. [38]).
Additionally, treatment of melanocytes with ␣MSH promotes terminal differentiation, resulting in an inhibition of
proliferation, and agouti reverses ␣MSH effects and inhibits pigmentation and promotes proliferation (39 – 41).
We have previously shown that agouti increases PPAR␥
expression in fully differentiated 3T3-L1 adipocytes and in
mice that ectopically express agouti in adipose tissue
2920

(12,13). The present study demonstrates that agouti stimulates adipocyte differentiation. Once again, the mechanism appears to be mediated through PPAR␥, since
PPAR␥ mRNA levels are as high in the confluent undifferentiated preadipocytes from agouti-expressing mice, as
compared with the fully differentiated adipocytes.
Perhaps the most clinically relevant findings are the
upregulation of human agouti by glucocorticoids and the
elevated levels of agouti and 11␤-HSD-1 mRNA in subcutaneous fat from patients with type 2 diabetes. Taken
together, these data suggest a model where by the hyperglycemia of diabetes activates 11␤-HSD-1 transcription
and increased local production of cortisol, which then
increases agouti mRNA. An alternate explanation is that a
common factor on induces both agouti and 11␤-HSD-1
transcription. Given that dexamethasone potently upregulates agouti in vitro, we hypothesize that the paracrine
model depicted in Fig. 6 is a more probable explanation
and warrants further investigation. 11␤-HSD-1 causes visceral obesity when overexpressed in transgenic mice (42),
but this effect is unlikely to be due to the upregulation of
agouti, as murine adipose tissue does not express agouti.
On the other hand, activity of 11␤-HSD-1 in human adipose
tissue is increased in visceral adipose tissue and has been
DIABETES, VOL. 52, DECEMBER 2003
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els in human adipose tissue. The influence of MCR signaling on adipogenesis combined with the well-established
role of MCR signaling in the hypothalamus suggest that
adipogenesis is coordinately regulated with food intake
and energy expenditure.
ACKNOWLEDGMENTS

This work was supported by American Heart Association
Scientist Development Grant 9630120N and National Institute of Diabetes and Digestive and Kidney Diseases Grant
R01 DK60747– 01A1 (to R.L.M.) and Bristol-Myers Squibb
Lipodystrophy initiative and U.S. Department of Agriculture Grant 34323-10704 (to S.R.S).
The authors also thank Estrellita “The PCR Princess”
Bermudez and Lauren Sparks for expert technical assistance.
REFERENCES
FIG. 6. Agouti regulation of adipogenesis: a working model. Increased
cortisol, either through the local production of cortisol by 11␤-HSD-1
or increased activity of the hypothalamic-ituitary-adrenal axis, leads to
increased agouti transcription. Agouti increases both proliferation (by
blocking the effects of ␣MSH) and differentiation (through the upregulation of PPAR␥ protein).

proposed as a cause of central adiposity (43). Our data
suggest that agouti might play a role in central obesity as
a downstream target of glucocorticoids. Cortisol might be
produced locally via 11␤-HSD-1 or the result of an overactive hypothalamic-pituitary-adrenal axis (44,45). Either
way, increased exposure of adipose tissue to cortisol
might serves as a stimulus for adipose tissue proliferation
and differentiation, and these data suggest that the autocrine/paracrine production of agouti is a putative mediator
of this effect.
When combined with previous studies in transgenic
mice overexpressing agouti, the functional implications of
increased agouti protein in adipose tissue are clear: agouti
blocks the antiproliferative effects of ␣MSH and promotes
preadipocyte differentiation (probably through the upregulation of PPAR␥). Thus, increased agouti is potentially
important as a paracrine factor in the regulation of adiposity, either during development or later in life. Given
that type 2 diabetes may be influenced by impaired adipogenesis and “spillover” of lipid into skeletal muscle and
liver (46), the upregulation of agouti mRNA in type 2
diabetes might be an attempt to proliferate and differentiate new adipocytes in order to store excess lipid in
adipose tissue.
In conclusion, mRNA levels were significantly elevated
in subjects with type 2 diabetes. The regulation of agouti in
cultured human adipocytes revealed that insulin did not
regulate agouti mRNA, whereas dexamethasone treatment
potently increased the levels of agouti mRNA. This finding,
as recapitulated in vivo in humans, where increased expression of the cortisol-activating enzyme 11␤-HSD-1 was
upregulated in concert with agouti in type 2 diabetes.
Experiments with cultured human preadipocytes and with
cells obtained from transgenic mice that overexpress
agouti demonstrated that MCR signaling in adipose tissue
regulates both preadipoycte proliferation and differentiation. Taken together, these results reveal that agouti can
regulate adipogenesis at several levels and suggest that
there are functional consequences of elevated agouti levDIABETES, VOL. 52, DECEMBER 2003

1. Bultman SJ, Michaud EJ, Woychik RP: Molecular characterization of the
mouse agouti locus. Cell 71:1195–1204, 1992
2. Miller MW, Duhl DM, Vrieling H, Cordes SP, Ollmann MM, Winkes BM,
Barsh GS: Cloning of the mouse agouti gene predicts a secreted protein
ubiquitously expressed in mice carrying the lethal yellow mutation. Genes
Dev 7:454 – 467, 1993
3. Fong TM, Mao C, MacNeil T, Kalyani R, Smith T, Weinberg D, Tota MR, Van
der Ploeg LH: ART (protein product of agouti-related transcript) as an
antagonist of MC-3 and MC-4 receptors. Biochem Biophys Res Commun
237:629 – 631, 1997
4. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS:
Antagonism of central melanocortin receptors in vitro and in vivo by
agouti-related protein [published erratum appears in Science 281:1615,
1998]. Science 278:135–138, 1997
5. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J, Baetscher M, Cone RD: A unique metabolic syndrome causes obesity
in the melanocortin-3 receptor-deficient mouse. Endocrinology 141:3518 –
3521, 2000
6. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield
LA, Burn P, Lee F: Targeted disruption of the melanocortin-4 receptor
results in obesity in mice. Cell 88:131–141, 1997
7. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U: Obesity in the
mouse model of pro-opiomelanocortin deficiency responds to peripheral
melanocortin. Nat Med 5:1066 –1070, 1999
8. Kwon HY, Bultman SJ, Loffler C, Chen WJ, Furdon PJ, Powell JG, Usala AL,
Wilkison W, Hansmann I, Woychik RP: Molecular structure and chromosomal mapping of the human homolog of the agouti gene. Proc Natl Acad
Sci U S A 91:9760 –9764, 1994
9. Wilson BD, Ollmann MM, Kang L, Stoffel M, Bell GI, Barsh GS: Structure
and function of ASP, the human homolog of the mouse agouti gene. Hum
Mol Genet 4:223–230, 1995
10. Voisey J, Imbeault P, Hutley L, Prins JB, Van-Daal A: Body mass indexrelated human adipocyte agouti expression is sex-specific but not depotspecific. Obes Res 10:447– 452, 2002
11. Mynatt RL, Miltenberger RJ, Klebig ML, Zemel MB, Wilkinson JE, Wilkinson WO, Woychik RP: Combined effects of insulin treatment and adipose
tissue-specific agouti expression on the development of obesity. Proc Natl
Acad Sci U S A 94:919 –922, 1997
12. Mynatt RL, Stephens JM: Agouti regulates adipocyte transcription factors.
Am J Physiol Cell Physiol 280:C954 –C961, 2001
13. Mynatt RL, Stephens JM: Regulation of PPAR-gamma and obesity by
agouti/melanocortin signaling in adipocytes. Ann N Y Acad Sci 994:141–
147, 2003
14. Janderova L, McNeil M, Murrell AN, Mynatt RL, Smith SR: Human
mesenchymal stem cells as an in vitro model for human adipogenesis. Obes
Res 11:65–74, 2003
15. Chagnon YC, Chen WJ, Perusse L, Chagnon M, Nadeau A, Wilkison WO,
Bouchard C: Linkage and association studies between the melanocortin
receptors 4 and 5 genes and obesity-related phenotypes in the Quebec
Family Study. Mol Med 3:663– 673, 1997
16. Boston BA, Cone RD: Characterization of melanocortin receptor subtype
expression in murine adipose tissues and in the 3T3–L1 cell line. Endocrinology 137:2043–2050, 1996
2921

AGOUTI EXPRESSION IN HUMAN ADIPOSE TISSUE

17. York DA, Bray GA: Dependence of hypothalamic obesity on insulin, the
pituitary and the adrenal gland. Endocrinology 90:885– 894, 1972
18. Hamm JK, el Jack AK, Pilch PF, Farmer SR: Role of PPAR gamma in
regulating adipocyte differentiation and insulin-responsive glucose uptake.
Ann N Y Acad Sci 892:134 –145, 1999
19. Morrison RF, Farmer SR: Insights into the transcriptional control of
adipocyte differentiation. J Cell Biochem (Suppl. 32-33):59 – 67, 1999
20. Morrison RF, Farmer SR: Role of PPARgamma in regulating a cascade
expression of cyclin-dependent kinase inhibitors, p18(INK4c) and
p21(Waf1/Cip1), during adipogenesis. J Biol Chem 274:17088 –17097, 1999
21. Spiegelman BM: Peroxisome proliferator-activated receptor gamma: a key
regulator of adipogenesis and systemic insulin sensitivity. Eur J Med Res
2:457– 464, 1997
22. Stephens JM, Morrison RF, Wu Z, Farmer SR: PPARgamma liganddependent induction of STAT1, STAT5A, and STAT5B during adipogenesis.
Biochem Biophys Res Commun 262:216 –222, 1999
23. Tontonoz P, Hu E, Spiegelman BM: Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor
gamma. Curr Opin Genet Dev 5:571–576, 1995
24. Wu Z, Rosen ED, Brun R, Hauser S, Adelmant G, Troy AE, McKeon C,
Darlington GJ, Spiegelman BM: Cross-regulation of C/EBP alpha and PPAR
gamma controls the transcriptional pathway of adipogenesis and insulin
sensitivity. Mol Cell 3:151–158, 1999
25. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor [published
erratum appears in Cell 80:957, 1995]. Cell 79:1147–1156, 1994
26. Darnell JEJ: STATs and gene regulation. Science 277:1630 –1635, 1997
27. Stephens JM, Morrison RF, Pilch PF: The expression and regulation of
STATs during 3T3–L1 adipocyte differentiation. J Biol Chem 271:10441–
10444, 1996
28. Stewart WC, Morrison RF, Young SL, Stephens JM: Regulation of signal
transducers and activators of transcription (STATs) by effectors of adipogenesis: coordinate regulation of STATs 1, 5A, and 5B with peroxisome
proliferator-activated receptor-gamma and C/AAAT enhancer binding protein-alpha. Biochim Biophys Acta 1452:188 –196, 1999
29. Wu Z, Bucher NL, Farmer SR: Induction of peroxisome proliferatoractivated receptor gamma during the conversion of 3T3 fibroblasts into
adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids.
Mol Cell Biol 16:4128 – 4136, 1996
30. Klebig ML, Wilkenson JE, Geisler JG, Woychik PR: Ectopic expression of
the agouti gene in transgenic mice causes obesity, features of type II
diabetes and yellow fur. Proc Natl Acad Sci U S A 92:4728 – 4732, 1995
31. Jones BH, Kim JH, Zemel MB, Woychik RP, Michaud EJ, Wilkison WO,
Moustaid N: Upregulation of adipocyte metabolism by agouti protein:

2922

possible paracrine actions in yellow mouse obesity. Am J Physiol 270:
E192–E196, 1996
32. Boston BA: The role of melanocortins in adipocyte function. Ann N Y Acad
Sci 885:75– 84, 1999
33. Cone RD, Lu D, Koppula S, Vage DI, Klungland H, Boston B, Chen W, Orth
DN, Pouton C, Kesterson RA: The melanocortin receptors: agonists,
antagonists, and the hormonal control of pigmentation. Recent Prog Horm
Res 51:287–317 [discussion 318], 1996
34. Yang YK, Ollmann MM, Wilson BD, Dickinson C, Yamada T, Barsh GS,
Gantz I: Effects of recombinant agouti-signaling protein on melanocortin
action. Mol Endocrinol 11:274 –280, 1997
35. Oelofsen W, Ramachandran J: Studies of corticotropin receptors on rat
adipocytes. Arch Biochem Biophys 225:414 – 421, 1983
36. Mountjoy KG, Wong J: Obesity, diabetes and functions for proopiomelanocortin-derived peptides. Mol Cell Endocrinol 128:171–177, 1997
37. Wolff GL, Roberts DW, Mountjoy KG: Physiological consequences of
ectopic agouti gene expression: the yellow obese mouse syndrome.
Physiol Genomics 1:151–163, 1999
38. Yen TT, Gill AM, Frigeri LG, Barsh GS, Wolff GL: Obesity, diabetes, and
neoplasia in yellow A(vy)/-mice: ectopic expression of the agouti gene.
FASEB J 8:479 – 488, 1994
39. Smalley K, Eisen T: The involvement of p38 mitogen-activated protein
kinase in the alpha-melanocyte stimulating hormone (alpha-MSH)-induced
melanogenic and anti-proliferative effects in B16 murine melanoma cells.
FEBS Lett 476:198 –202, 2000
40. Suzuki I, Tada A, Ollmann MM, Barsh GS, Im S, Lamoreux ML, Hearing VJ,
Nordlund JJ, Abdel-Malek ZA: Agouti signaling protein inhibits melanogenesis and the response of human melanocytes to alpha-melanotropin.
J Invest Dermatol 108:838 – 842, 1997
41. Sviderskaya EV, Hill SP, Balachandar D, Barsh GS, Bennett DC: Agouti
signaling protein and other factors modulating differentiation and proliferation of immortal melanoblasts. Dev Dyn 221:373–379, 2001
42. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR,
Flier JS: A transgenic model of visceral obesity and the metabolic
syndrome. Science 294:2166 –2170, 2001
43. Bujalska IJ, Kumar S, Stewart PM: Does central obesity reflect “Cushing’s
disease of the omentum”? Lancet 349:1210 –1213, 1997
44. Bjorntorp P, Holm G, Rosmond R: Hypothalamic arousal, insulin resistance and type 2 diabetes mellitus. Diabet Med 16:373–383, 1999
45. Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi L, Flamia R,
Labate AM, Barbara L: The hypothalamic-pituitary-adrenal axis in obese
women with different patterns of body fat distribution. J Clin Endocrinol
Metab 77:341–346, 1993
46. Danforth E Jr: Failure of adipocyte differentiation causes type II diabetes
mellitus? (Letter). Nat Genet 26:13, 2000

DIABETES, VOL. 52, DECEMBER 2003

